Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HARVARD BIOSCIENCE INC Regulatory Filings 2009

Aug 6, 2009

34975_rns_2009-08-06_21e7a366-9dcd-4b6a-a12c-138eafb99349.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

8-K 1 document.htm FORM 8-K FILING DOCUMENT html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Form 8-K Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 6, 2009

HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter)

Registrant's State of Inc, File and IRS Number

Delaware 001-33957 04-3306140
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Registrant's Postal Addess and Zip Code

84 October Hill Road, Holliston, MA 01746
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (508) 893-8999

________________________________________________________________________________ (Former name or former address, if changed since last report)

Simultaneous filing obligation checkboxes

| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation

of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On August 6, 2009, Harvard Bioscience, Inc., (the "Company") issued a press release announcing financial results for the three and six months ended June 30, 2009. The press release is furnished as Exhibit 99.1 and incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Title
99.1 Press release of Harvard Bioscience, Inc. issued on August 6, 2009.

Registrant's Signature

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARVARD BIOSCIENCE, INC. (Registrant)
August 6, 2009 (Date) /s/ THOMAS MCNAUGHTON Thomas McNaughton Chief Financial Officer & Principal Accounting Officer